Tanezumab, an antibody to nerve growth factor, was administered to pregnant cynomolgus monkeys at 0, 0.5, 4, and 30 mg/kg weekly, beginning gestation day (GD) 20 through parturition ($GD165). Maternal tanezumab administration appeared to increase stillbirths and infant mortality, but no consistent pattern of gross and/or microscopic change was detected to explain the mortality. Offspring exposed in utero were evaluated at 12 months of age using light microscopy (all tissues), stereology (basal forebrain cholinergic and dorsal root ganglia neurons), and morphometry (sural nerve). Light microscopy revealed decreased number of neurons in sympathetic ganglia (superior mesenteric, cervicothoracic, and ganglia in the thoracic sympathetic trunk). Stereologic assessment indicated an overall decrease in dorsal root ganglion (thoracic) volume and number of neurons in animals exposed to tanezumab 4 mg/kg (n ¼ 9) and 30 mg/kg (n ¼ 1). At all tanezumab doses, the sural nerve was small due to decreases in myelinated and unmyelinated axons. Existing axons/ myelin sheaths appeared normal when viewed with light and transmission electron microscopy. There was no indication of tanezumab-related, active neuron/nerve fiber degeneration/necrosis in any tissue, indicating decreased sensory/ sympathetic neurons and axonal changes were due to hypoplasia or atrophy. These changes in the sensory and sympathetic portions of the peripheral nervous system suggest some degree of developmental neurotoxicity, although what effect, if any, the changes had on normal function and survival was not apparent. Overall, these changes were consistent with published data from rodent studies.
kinase receptor trkA, and the tumor necrosis factor (TNF) family receptor p75 (Smeyne et al., 1994) . TrkA is highly selective for NGF over other neurotrophins, whereas p75 binds all neurotrophins with similar affinities (Abdiche et al., 2008) . NGF has been investigated primarily in early neuronal development and is the first example of a molecule that functions as described in the neurotrophic hypothesis (Levi-Montalcini and Hamburger, 1951; Mantyh et al., 2011) . This hypothesis states that neurons are overproduced during development and naturally occurring cell death after target innervation reduces the population via limited availability of neurotrophic factors (Levi-Montalcini and Hamburger, 1951) . Exposure to sufficient neurotrophic factor allows neuron survival, whereas low levels lead to programmed cell death. In subpopulations of peripheral neurons in rodents and birds, NGF has all of the properties of a neurotrophic factor under these criteria (Crowley et al., 1994; Levi-Montalcini and Hamburger, 1951) .
In adult neurons, NGF has a role as a mediator of pain (Bennett et al., 1998) . NGF is dramatically upregulated in pain conditions, especially inflammatory pain (McMahon, 1996; Wu et al., 2007) . This upregulation can be caused by common inflammatory mediators, such as TNF-a and interleukin-1b (Hattori et al., 1996; Steiner et al., 1991) . Injection of NGF causes an increase in behavioral signs of hyperalgesia in rodents and a long-lasting increase in pain sensitivity in human subjects (Dyck et al., 1997; Lewin et al., 1993; Svensson et al., 2003) . Blocking NGF decreases pain-related behavior in several animal models (Shelton et al., 2005; Zahn et al., 2004) and has led to clinical trials of NGF inhibitors, primarily monoclonal antibodies. These trials in chronic pain conditions have shown robust pain relief (Brown et al., 2012; Evans et al., 2011; Katz et al., 2011; Lane et al., 2010) . Given the clinical potential of NGF monoclonal antibodies, the paucity of data on developmental effects of NGF deprivation in primates, and the potential benefit in females of child bearing potential with pain conditions, the neuropathologic consequences in offspring following maternal exposure to a monoclonal antibody blocking NGF action throughout pregnancy in nonhuman primates was evaluated.
MATERIALS AND METHODS
This article focuses on the comprehensive neuropathologic evaluation of young nonhuman primates from a developmental toxicity study of tanezumab. A more detailed description of the overall study has been submitted for publication separately. Four groups of pregnant cynomolgus monkeys (n ¼ 18 per group) received weekly intravenous injections of tanezumab at the following doses: 0 mg/kg (vehicle control), 0.5 mg/kg, 4 mg/kg, or 30 mg/kg starting on gestation day (GD) 20 (early organogenesis) and continuing until parturition (approximately GD165; Table 1 ). Tanezumab was detected in infant plasma samples up to DB (days after birth) 30, DB120, and DB127 in the 0.5, 4, and 30 mg/kg groups, respectively.
Tanezumab, a humanized immunoglobulin G (IgG) 2Da monoclonal antibody against NGF, was manufactured and supplied by Pfizer Inc. (Shanbally, Ireland) in 10 mM histidine, 84 mg/ml trehalose, 0.1 mg/ml polysorbate 20, and 0.05 mg/ml ethylenediaminetetraacetic acid (EDTA) buffer, with a pH of 6.0.
The in-life phase of these studies was conducted at the SNBL USA Test Facility (Everett, WA) in accordance with the U.S. Food and Drug Administration Good Laboratory Practices. Study animals were healthy, purpose-bred, nulliparous, and experimentally naïve female cynomolgus monkeys (Macaca fascicularis) originating from Indonesia. Animals were housed in a temperature-and humidity-monitored environment (18 C-29 C and 30%-70%, respectively), where an automatic lighting system provided a 12 h diurnal cycle. Maternal animals and weaned infants were fed LabDiet V R Laboratory Fiber-Plus V R biscuits (PMI Nutrition International LLC, St Louis, MO) twice daily. Cages for housing were used according to the Animal Welfare Act and recommendations set forth in the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) . The test facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care with oversight by an institutional animal care and use committee.
Offspring of tanezumab-treated pregnant nonhuman primates were scheduled for euthanasia at approximately 12 months of age. Those animals euthanized on schedule were sedated, weighed, and deeply anesthetized with pentobarbital. A whole-body perfusion was performed via cannulation of the left ventricle and a phosphate-buffered saline (PBS) flush followed by 4% methanol-free formaldehyde. Stillborn offspring and animals found dead did not undergo whole-body perfusion. Instead, tissue fixation for these animals occurred via immersion into 10% neutral-buffered formalin (NBF) and tissue collection varied depending on tissue condition.
There were sufficient early deaths/early euthanasia in this study that the data were analyzed in 2 general subsets: (1) early deaths/early euthanasia, including stillbirths, and (2) scheduled terminal and near-scheduled terminal (close to the time of the scheduled) euthanasia. The scheduled term/near-term category included those animals that survived until approximately 12 months of age and 1 animal euthanized (moribund condition associated with fracture, considered unrelated to tanezumab exposure) at 338 days of age.
Tissue Preparation: Light Microscopy (All Animals) The left brain was placed into 10% NBF, embedded in paraffin, and sectioned (transverse/coronal plane) to yield approximately 15 sections spanning the prefrontal cortex through the brain stem. In general, these 15 sections included the following regions: cerebral cortex and associated white matter (sections 1-14, including 1 or more sections of the frontal, parietal, temporal, and occipital lobes including the cingulate gyrus), caudate/putamen (sections 2-3), thalamus/hypothalamus (sections 4-6), midbrain (sections 7-10), hippocampus (sections 9-10), pons region (sections 10-11), cerebellum (sections 12-14), and medulla oblongata (sections 12-15). Sections were stained with hematoxylin and eosin (H&E), a standard cell stain used for the majority of preclinical safety studies; glial fibrillary acidic protein (GFAP), a marker for astrocytes, using standard Number of infants b avidin-biotin immunohistochemical methods (Towle et al., 1984) ; and fluoro-jade B (FJB), a stain allowing for sensitive and selective identification of necrotic neurons in the central nervous system (Schmued and Hopkins, 2000) . Spinal cord segments (cervical, thoracic, and lumbar; transverse and oblique sections at each level) were placed into 10% NBF, embedded in paraffin, sectioned, and stained with H&E, GFAP, and FJB. Samples of cervical, thoracic, and lumbar dorsal and ventral roots and ganglia were placed into 10% NBF, embedded (longitudinally so each section included ganglion and dorsal/ventral roots) in paraffin and stained with H&E and FJB.
The left cervicothoracic ganglion and the superior mesenteric ganglia were placed into 2.5% glutaraldehyde/2% formaldehyde for 48 h, then into PBS and stored refrigerated until processing, embedded in paraffin, and stained with H&E and FJB.
From the sciatic, tibial, sural, and vagus nerves, and a segment of the thoracic sympathetic trunk, a segment was harvested and placed into 2.5% glutaraldehyde/2% formaldehyde for 48 h, then placed into PBS and stored refrigerated until processing. The right side was embedded (longitudinal orientation) in paraffin and stained with H&E. The left side (embedded transversely) was embedded in resin as preparation for light (thick sections) and transmission electron microscopic (TEM; thin/grid supported cross-sections) evaluation (see below).
The trigeminal ganglia were placed into 4% methanol-free formaldehyde (48-72 h), transferred to 2.5% glutaraldehyde/2% formaldehyde for 48 h, then placed into PBS and stored refrigerated until processing. The left trigeminal ganglia was embedded in paraffin (longitudinal orientation to include the trigeminal nerve and its branches) and stained with H&E and FJB.
The following tissues were preserved in 10% NBF, embedded in paraffin (standard orientations), sectioned, stained with H&E, and examined: adrenals, cecum, colon, duodenum, epididymides, esophagus, gall bladder, heart, ileum, jejunum, joint (knee, left), kidneys, liver, lymph nodes (axillary), lymph node (mesenteric), lung, mammary gland (females), ovaries, oviducts, pancreas, parathyroid glands, prostate gland, salivary glands, seminal vesicles, skeletal muscles, skin with adnexa, spleen, sternum (with marrow), stomach, thymus, thyroid gland, tongue, trachea, ureters, urinary bladder, uterus, and vagina. The eyes and testes were preserved in modified Davidson's fluid, then processed and examined in a manner similar to the other tissues.
Tissue Preparation: Stereology (Perfusion-fixed Animals Only) Brain. Following perfusion fixation, the right brain was placed into 4% methanol-free formaldehyde and refrigerated for an additional 24 h following collection. The brain was then transferred to cacodylate buffer and refrigerated until processing (by NeuroScience Associates, Knoxville, TN). During processing, the brain was embedded in gelatin, frozen on a freezing/sliding microtome, and sectioned through the basal forebrain area to include the medial septal nucleus, nuclei of the diagonal band, and the nucleus basalis of Meynert. The brains were sectioned at approximately 40 m in the transverse plane. All sections were collected into a series of wells containing antigen preservation solution. For immunohistochemistry, every 12th section in the rostral brain containing the diagonal band of Broca and caudal to that (to the end of the caudate) every 24th section was stained free floating. All incubation solutions from the blocking serum onward used Tris-buffered saline (TBS) with TritonX-100 as the vehicle; all rinses were with TBS. After a hydrogen peroxide treatment and blocking serum, the sections were immunostained with the primary antibody (choline acetyl transferase [ChAT] ; source ¼ Millipore [Chemicon], Temecula, CA; host: Goat; dilution ¼ 1:1000). Vehicle solutions contained TritonX-100 for permeabilization. Following rinses, a biotinylated secondary antibody (Vector Laboratories Vecta Elite rabbit anti-goat) was applied. After further rinses, Vector Laboratories VECTASTAIN Elite ABC (avidin-biotin-horse radish peroxidase complex) Kit (Vector Laboratories, Inc., Burlingame, CA) was applied. After rinses, the sections were treated with diaminobenzidine (DAB) and hydrogen peroxide to create a visible reaction product and following rinses, sections were mounted on gelatin-coated glass slides, air-dried, dehydrated in alcohols, cleared in xylene, and cover slipped. Dorsal Root Ganglia. One or two ganglia from the mid-thoracic region were processed in the same gelatin block. This block was cryoprotected and sectioned completely through with sections distributed into a series of 2-4 individual wells. Each section included portions of 1 or both ganglia. Ganglia were treated as a single tissue for analysis purposes. Sections from 1 or more wells (sufficient to include at least 8-10 sections evenly spaced throughout the ganglia) were mounted on glass slides and stained with cresyl violet to identify neurons. Section hydration was maintained by an aqueous mounting/cover slip media.
Tissue Preparation: Transmission Electron Microscopy (Perfusion-fixed Animals) From perfusion-fixed animals, left peripheral nerves (sciatic, tibial, and sural), vagus nerve, thoracic sympathetic trunk, a dorsal and ventral spinal root/rootlet, and one dorsal root ganglion from the C6 to T1 and L5 to S1 regions were collected at necropsy and post-fixed in 2.5% glutaraldehyde/2% formaldehyde in 0.1 M phosphate buffer. At 48 6 4 h later, samples were transferred to individual vials filled with PBS and refrigerated until processing. Samples were trimmed, transferred to 0.1 M phosphate buffer, and rinsed three times for 10 min each, and fixed in Dalton's chrome osmium for 2 h at 4 C followed by 2 rinses with deionized water. Samples were dehydrated via a graded ethanol series and propylene oxide prior to overnight infiltration with propylene oxide/resin mixture before transfer to fresh resin for 2 h prior to embedding. Following polymerization, 0.5 mm sections were cut using a Leica Ultracut ultramicrotome, stained with toluidine blue (a nucleic acid-and polysaccharide-specific stain; demonstrates myelin and cell detail), and evaluated by light microscopy. Thin sections were cut at 75-90 nm, mounted on 200-mesh copper palladium grids, stained with uranyl acetate and lead citrate, and evaluated using a Hitachi 7100 TEM at 75 kV by the study pathologist. Digital images for sural nerve morphometry were captured using a digital charge-coupled device (CCD) camera system (Advanced Microscopy Techniques, Danvers, MA).
Evaluation: Light Microscopy
All microscopic evaluations (primary reviews and a peer review) were conducted by board certified veterinary pathologists. These evaluations included:
• Paraffin-embedded, H&E-, FJB-, and/or GFAP-stained sections of the brain, spinal cord, peripheral nerves (including spinal nerve roots), ganglia (dorsal root, trigeminal, sympathetic, and parasympathetic), and all other tissues listed above, including all of the non-nervous system tissues.
• ChAT-stained brain sections (used for stereologic evaluation of cholinergic neurons in the basal forebrain).
• Toluidine blue-stained, resin embedded sections of the peripheral nerves, vagus nerve, spinal nerve roots and ganglia, and thoracic sympathetic trunk (including those sections prepared as a preliminary step towards TEM).
• Frozen sections, cresyl violet-stained, produced for stereology of the dorsal root ganglia.
Evaluation: Transmission Electron Microscopy
All prepared thin sections on mesh grids for processed tissues from perfusion-fixed animals were directly examined by the study pathologist using a TEM.
Evaluation: Stereology
All stereology evaluations were performed by a trained technician who was blinded to treatment of the animals/specimens. The study pathologist, also blinded to treatment, determined the suitability of the sections for stereologic evaluation and defined the region of interest (ROI) for each investigation. The stereologic investigations were performed using Stereologer V R software (Stereology Resource Center, Chester, MD), which drives an automated stage mounted on a compound microscope with objectives of a suitable quality to define thin optical planes in tissue sections. Coefficient of error (CE), an estimate of the contribution of the methodology (specimens and the methods used to analyze the specimens) to the total variance that might be expected between samples, was calculated by the Stereologer V R software (Gundersen et al., 1999) . This value reflects on the variability of the estimated mean with respect to the population mean. A CE of less than 10% is assumed to ensure a stable and accurate study design. For these investigations, the CE was typically in the range of 1%-3% for the estimation of ganglion volume, 7%-9% for the estimation of neuron numbers in ganglia, and below 15% for the estimation of myelinated axon numbers and sural nerve size.
Frozen sections of the basal forebrain region (40 mm) were stained with ChAT and evaluated for the following parameters:
• Volume of the ROI (basal forebrain structures): The ROI was the nuclei of the diagonal band and the nucleus basalis of Meynert. Because the medial septal nuclei are midline structures, and bisecting the brains may have impacted that structure in some animals, the ROI used for this stereologic investigation did not include the medial septal nuclei. The majority of the cholinergic neurons in the human basal forebrain are in the nucleus basalis of Meynert/Cholinergic cell group 4 (Mesulam and Geula, 1988) and, based on the observations of the author (M.B.), the same is true for the cynomolgus monkey. Figure 1A shows an example of the outline (determined at the beginning of the stereologic examination of each section) of a portion of the nucleus basalis of Meynert. The image is a frame capture from the stereology software, and the resolution is limited to that of the program.
• Total ChAT-positive (ChATþ; i.e., cholinergic) neurons in the ROI: Fig. 1B shows an example of two neurons counted within a disector frame. Neurons were counted if the main body of the cell (excluding the axons and dendrites) was inside the disector frame and not touching an exclusion (red) line, or if they were touching an inclusion (green) line and not touching an exclusion line. Neurons were only counted if the "top" of the neuron first came into focus within the frame height, meaning that the top point (in a three-dimensional space) of the neuron was what determined its inclusion. This was done to prevent the theoretical counting of neurons in multiple sections (i.e., if the top of a neuron was determined to be above the frame height, it was assumed that the neuron had been counted in the section just above the section being evaluated).
Frozen sections of 1 or 2 thoracic dorsal root ganglia (50 mm) with cresyl violet stain were evaluated for the following parameters:
• Volume of the ROI (ROI ¼ ganglia): 1 or 2 dorsal root ganglia (analyzed as one tissue).
• Total number of neurons in the ROI.
• Average cross-section area of the neurons (calculated by determining the average radius at the level of the nucleolus).
For those animals where a single ganglion was analyzed, the data regarding neuron counts and volume of the ROI were doubled in order to be comparable with those animals in which two ganglia were analyzed.
The volume of the ROI was determined using the Cavalieri method (Mouton, 2002) . For this calculation, the stereology software multiplied the area of each ganglia section by the average section thickness to obtain the section volume. The sum of the volume of the examined sections multiplied by the inverse of the section sampling fraction (SSF; the number of sections examined divided by the total number of sections through the entirety of the ROI) was the total estimated ganglion volume.
Neuron counts were performed using the optical fractionator method (Mouton, 2002) . Total calculated neurons (the object of interest) were determined according to the following equation:
Total calculated objects ¼ objects actually counted Â 1/SSF Â 1/TSF Â 1/ASF Tissue or thickness sampling fraction (TSF) is the height of the disector (a three-dimensional counting probe/counting frame for counting objects in a thick tissue section) frame/optical fractionator divided by the average thickness of the section. Area sampling fraction (ASF) is the area of the disector divided by the distance the disectors are apart (in the x and y directions) squared. Stated another way, if the ROI in each section was divided into square grids with sides x and y, then the ASF would be the proportion of each grid occupied by the disector (Mouton, 2002) .
For cholinergic neuron counts, the following parameters were used:
• Â63 oil objective • Disector height: 8 mm; average section thickness varied (due to shrinkage of the sections that may occur during drying/staining), but was typically in the 10-11 mm range; therefore, TSF ¼ 0.67 or 0.73; 1/TSF ¼ 1.49 or 1.37 (for a section thickness of 10 mm or 11 mm, respectively).
• The number of sections through the ROI varied, so the SSF varied. Typically, the SSF was in the range of 0.05 (1/SSF ¼ 20)
• The counting point was the top of each neuron (when the neuron first came into focus within the disector/optional fractionator frame).
For the dorsal root ganglia neuron counts, the following parameters were used:
• Â60 oil objective • Disector size: 4000 mm 
Evaluation: Quantification of Myelinated Nerve Fibers
Resin-embedded, 0.5 mm thick, toluidine blue-stained sections of the sural nerve were evaluated for the following parameters: nerve cross-sectional area, total myelinated nerve fibers (MNFs), average MNF radius, average axon radius, and g-ratio (defined as the ratio of the axon diameter to the diameter of a single MNF).
In order to conduct unbiased measurements/counts, the evaluations were performed using the optical disector method employed by the same stereology software program (Stereologer V R ) and equipment used to conduct the stereologic investigations. The nerve cross-section area was directly measured using DP2-BSW Software, (Olympus Corporation, version 2.1 Build 6207) and was also calculated by the stereology program using the Cavalieri method (Gundersen et al., 1999) . The total number of MNFs was determined using the optical disector method and calculated according to the equation:
Total calculated objects ¼ objects actually counted Â 1/ASF For this investigation, SSF ¼ 1 because one section was examined, and TSF ¼ 1 because the structures counted (nerve fibers) spanned the entire thickness of the section due to their orientation. The ROI was the nerve cross-section. The software selected disectors across the nerve in a systematic random manner using the following parameters: disector size: 100 mm 2 , and disector spacing: 21-32 mm (depending on nerve cross-section area).
Evaluation: Quantification of Unmyelinated Nerve Fibers
To quantify unmyelinated nerve fibers (UNFs) in the sural nerve, electron photomicrographs taken of the thin (75À90 nm) sections mounted on grids used to perform the TEM evaluations were used. The following procedure was followed:
1. On low power (Â100) using the electron microscope, the best section of the entire nerve cross-section to be examined was selected. This magnification did not allow for evaluation of UNFs. Selection criteria included placement of the section on the grid to allow the entire nerve to be photographed. 2. Images were taken in a systematic (regular spacing of grid lines) and random (grid-line intersections used as random points) manner. 3. A digital image was produced at each grid line intersection on the nerve (the nerve being defined as the tissue within the perineurium [the surrounding connective tissue sheath]). Figure 2 shows the areas that served as the reference points (arrows point to grid corners on the nerve). 4. Image capture procedures were as follows:
i. Each grid corner was moved to the closest edge of the monitor/display used to capture digital images. ii. The corner was placed such that an equal amount of space (black area on the grid lines) was on each side of the corner and the orientation retained. iii. The image was moved toward the side of the screen where the corner touched the edge, maintaining an equal amount of black on each side of the corner. Once the entire screen was filled with nerve, the image was captured. 5. The individual images were subsampled with the goal of counting approximately 150 UNFs in each nerve and used appropriate multipliers to arrive at the total number of UNFs per nerve.
FIG. 2.
A digital image that shows the areas that served as the reference points for tissue within the perineurium (the surrounding connective tissue sheath). The arrows show the reference points (grid corners) overlying the nerve. For this nerve, a total of 28 images at Â1500 were captured. The grid intersects provide an unbiased, systematic set of sampling points that span the entirety of the nerve.
The ROI for this analysis was the sural nerve cross-section. Each nerve was analyzed to determine the total estimated number of UNFs.
ImageJ software (http://rsb.info.nih.gov/ij/; used to analyze the nerve for UNFs) was calibrated using a scale bar digitally embedded in the low-power image. The perimeter of the nerve was traced on the low-power image and the software calculated the cross-section area. Counts were performed on high-power images with a grid superimposed by the software.
After the image was calibrated for scale, a randomly offset grid of 50 mm 2 frames was placed onto the image by the software. The number of frames analyzed depended on the number of high-power images available per nerve. A random list was generated to provide the order in which frames would be analyzed. For example, if only two frames were deemed necessary to achieve a count of approximately 150 UNFs (as determined in the pilot investigation), the first 2 randomly chosen frames would be analyzed for each image for that particular animal. For the purposes of this investigation, frames were numbered left to right, top to bottom (Fig. 3) . Individual UNFs were counted in the appropriate frames for all images per animal. Frames that were on an area with a nerve that did not contain any UNFs were recorded as zero; frames that were not on an area with a nerve image were recorded as a hyphen (-) . If the frame to be counted was not on the nerve, then that frame was not included in the total area of the grid frames counted. This was necessary so as not to incorrectly calculate the key components for determining the total UNFs, specifically actual UNFs counted, total area of the grid frames counted, and total area of the nerve.
Only the center point of each UNF was counted. Selecting the center point of each UNF was necessary because reducing each UNF to a single point for counting purposes eliminated any bias towards over counting larger UNFs as compared with smaller UNFs. If a center point was directly on a grid line, the top and right grid lines were considered inclusive (meaning the UNF would be counted for that frame); the bottom and left lines were considered exclusive (meaning the UNF would not be counted in that frame).
Some nerves were deemed to be of insufficient quality for evaluation or morphometric analysis because the unmyelinated fibers were dark, indistinct, and/or lacked sufficient detail to allow for identification of individual UNFs.
Statistical Evaluations
The stereology and morphometry data were statistically analyzed for tanezumab-exposed offspring versus controls. To determine any statistical significance between groups, an independent, twotailed t-test was performed. No hypothesis was made on which group would have greater values. Data from male and female offspring were combined. Statistical analyses did not include the 30 mg/kg tanezumab group because only a single animal was evaluated via stereologic and morphometric analyses. Table 2 summarizes the cases of mortality/early euthanasia in this study. During the morphologic evaluation, only those animals classified as moribund euthanasia, found dead, or stillborn (except as noted in footnotes a and b in Table 2 ) were evaluated. There was no definitive set of morphologic changes in nervous system tissue that correlated to the occurrence of stillbirth or postnatal infant mortality. Four of the 14 infants in the 30 mg/kg group that died or were euthanized early had evidence of lung inflammation, suggesting a possible viral pneumonia. Based on the total numbers of found dead and stillborn animals as considered and analyzed during the morphologic evaluation phase of this study, there was no strong evidence of an effect of tanezumab on offspring survival except at the 30 mg/kg dose. However, when results from this study and a companion study were reviewed and the timing of fetal/infant loss, including   FIG. 3 . The grid overlay produced by ImageJ is shown on a digital image of the sural nerve. The order of grid numbering is shown. The horizontal lines in the center of some frames indicate which frames would be recorded as not containing nerve, and would not be considered when measuring the total area analyzed (frames were required to contain at least 50% nerve to be counted). The arrows indicate clusters of unmyelinated nerves that would be counted assuming those frames were required for that nerve. As an example, if it was determined that only two frames per image needed to be analyzed, and those two frames were randomly determined to be frames #1 and #10, these frames would be recorded as containing 10 and 0 unmyelinated nerve fibers, respectively. One aborted fetus (aborted on GD119) was examined and reported. d One aborted fetus (aborted on GD129) was examined and reported.
RESULTS

Mortality/Moribundity
pregnancy loss, was considered, maternal tanezumab administration appeared to increase stillbirth and postbirth infant mortality/morbidity and decrease infant growth at all doses.
Light Microscopy
There were no tanezumab-related microscopic findings in the central nervous system (brain or spinal cord) and no evidence of active neuronal or axonal degeneration in any of the nervous system tissues. Use of standard H&E staining and FJB staining of paraffin-embedded sections of the brain, spinal cord, sympathetic ganglia, and dorsal root ganglia did not reveal any active/ ongoing neuronal death or degeneration. H&E stained, paraffinembedded sections of brain, spinal cord, ganglia, and peripheral nerves did not reveal any test article-related active axonal degeneration. TEM evaluation of dorsal root ganglia, spinal nerve roots, sympathetic ganglia, and sciatic/tibial/sural/vagus nerves did not reveal any test article-related active neuronal or axonal degeneration. Tanezumab-related morphologic findings in the nervous system were seen in the peripheral nervous system only and are summarized in Table 3 . There were no direct or indirect effects of tanezumab in the non-nervous system tissues of the term/near-term sacrifice infants. Indirect tanezumab effects in the skin (ulceration and chronic/active inflammation), lung (pneumonia [inflammation]), thymus, and spleen (decreased lymphocytes) noted in the early death/early sacrifice infants were either not present in the term/near-term sacrifice infants or were not present at an incidence/average severity to suggest a relationship to tanezumab.
At all tanezumab doses (administered as 0.5, 4, and 30 mg/kg to the dams), light microscopic evaluation revealed neurons in the superior mesenteric ganglion, cervicothoracic ganglion, and the ganglia of the thoracic sympathetic trunk were decreased in number as compared with control animals (Fig. 4A-D) . Treatment-related effects on the superior mesenteric and cervicothoracic ganglia were noted in animals that died or were euthanized early and offspring evaluated at term/near-term. Effects on the thoracic sympathetic trunk were only evaluated thoroughly in the term/near-term animals. The thoracic sympathetic trunk (Fig. 5A and B) and the cervicothoracic ganglion were small (reduced in size in the sections examined microscopically, suggesting a reduction in volume) as compared with the control animals (an actual quantitative investigation was not performed). The magnitude of the effect was similar in all tanezumab-treated groups.
The neurons in the sympathetic ganglia were morphologically normal. There was no evidence of active or on-going neuronal or axonal degeneration/necrosis associated with tanezumab exposure. The sural nerve in the occasional 0.5 mg/ kg and most 4 mg/kg tanezumab-exposed, terminal sacrifice animals was small (based on morphologic evaluation) compared to control animals. This was confirmed via morphometric (specific measurement of cross-section area) investigation (see below).
Stereologic Findings
Basal Forebrain Cholinergic Neurons. There was no effect on the number of cholinergic neurons in the basal forebrain (Table 4) .
Thoracic Dorsal Root Ganglia. In animals evaluated at approximately 1 year of age, exposure to tanezumab during gestation resulted in a statistically significant (P < .05) decrease in dorsal root ganglia volume and total number of neurons in infants of dams that received 4 mg/kg tanezumab compared with control The incidence is the number affected/number of that specific tissue examined in that group. The percentage affected is also provided. Males and females are combined.
c
The average severity ¼ all severity scores for a finding (per group) divided by number of specific tissue examined in that group.
d
Not considered test article related in this group.
e Thick/toluidine blue-stained sections produced at Pfizer Drug Safety Research and Development (Pfizer Inc, Groton, CT). Sections suitable for this determination were available only for animals euthanized as scheduled at Term/ Near-Term.
Inc, incidence; Avg. Sev., average severity; SMG, superior mesenteric ganglion; À, finding not present in dose group; CCG, cervicothoracic ganglion; NP, analysis not performed. (Table 5 ). The mean neuron (soma) size was increased in these animals. This was consistent with smaller neurons being preferentially affected (failed to develop or possibly atrophied). Figure 6 shows a histogram of a neuron cross-section area measured at the level of the nucleolus for the term/near-term animals. A decrease in ganglion volume and total neurons was present in the single offspring from the 30 mg/kg group evaluated stereologically. In terms of neuron counts, the data in
FIG. 4. Representative images of:
A, control superior mesenteric ganglion; B, tanezumab-exposed (0.5 mg/kg) superior mesenteric ganglion; C, control cervicothoracic ganglion; and D, tanezumab-exposed (4 mg/kg) cervicothoracic ganglion. The sympathetic ganglia in tanezumab-exposed animals contained fewer neurons as compared to the same ganglia in control animals. The cervicothoracic ganglia (and likely also the superior mesenteric ganglia) were consistently small in tanezumabexposed animals.
FIG. 5. Representative images of:
A, control (scheduled term) sympathetic trunk (arrows); and B, tanezumab-exposed (4 mg/kg, scheduled term) sympathetic trunk. In tanezumab-exposed animals, the sympathetic trunk was consistently small as determined by viewing the cross section thickness of thick sections. Note that in Figure   5B , the sympathetic trunk appears to be more densely cellular than the control sympathetic trunk. This was interpreted to be due to a relative increase of Schwann cells associated with atrophied axons rather than an absolute increase. that single animal were similar to the average group data in the tanezumab 4 mg/kg exposure group. Decreased ganglion volume, decreased total neuron counts, and increased average neuron area were considered probable effects associated with prenatal exposure to tanezumab at the 0.5 mg/kg dose, although differences did not reach statistical significance from controls (Table 6 ). In animals that died or were euthanized early, insufficient data were available for statistical analyses regarding dorsal root ganglia volume, estimated total neurons, and average neuron size since only two control animals were available for comparison. Regarding the total estimated (calculated) number of neurons, 1 of 2, 3 of 3, and 6 of 6, exposed animals (in the 0.5, 4, and 30 mg/kg groups, respectively) had estimated total neurons outside (below) the range set by the two available controls.
Quantitative/Morphometric Findings Sural Nerve-MNFs. Offspring exposure to tanezumab as a result of maternal dosing during pregnancy resulted in a decrease in the cross-section area of the sural nerve, which correlated to a decrease in the total number of MNFs. This effect did not appear to have a predilection for any particular size of MNF, since no The reason for this lack of a correlation was not apparent. It is possible the lumbosacral dorsal root ganglia (which were not examined stereologically) were affected differently than the thoracic dorsal root ganglia, or the neuron soma may have been affected differently (in terms of atrophy) than the axon. Sural Nerve-UNFs. Offspring exposure to tanezumab as a result of maternal dosing during pregnancy caused a statistically significant decrease in the total number of UNFs present in the sural nerve at doses of 0.5 mg/kg and 4 mg/kg. This decrease in total number was present in a dose-related manner, with a decrease of approximately 60% in UNFs at 0.5 mg/kg, a 90% decrease at 4 mg/kg, and >99% decrease in the single 30-mg/kg animal analyzed (Table 8) .
DISCUSSION
An abundant amount of literature exists in rodents on the effects of "anti-NGF states" induced through the production of knockout mice or administered antibodies to the NGF receptors.
To the knowledge of the authors, this is the first report of the morphologic nervous system effects in nonhuman primate offspring with presumed prenatal exposure to an anti-NGF antibody following maternal administration during pregnancy (commencing on GD20 and continuing weekly until the end of gestation). Based on information on placental transfer of IgG antibodies in nonhuman primates (Coe et al., 1993; Fujimoto et al., 1983; Moffat et al., 2014) , it would be expected that there might be low embryo-fetal exposure by the end of organogenesis (GD50), with levels increasing until birth. The tanezumab exposure in infants (detectable until 1, 4, and 4 months of age in the 0.5, 4, and 30 mg/kg groups, respectively) is consistent with high placental IgG transfer during the third trimester and negligible via milk transfer (Pentsuk and van der Laan, 2009 ). Numerous reports have associated the inhibition of the NGF receptors with morphologic abnormalities in rodents. Antibodies to NGF receptors (either exogenous or endogenously produced) result in numerous effects in sympathetic ganglia, including shrunken and degenerating neurons in the superior cervical ganglion (Bode et al., 1986; Businaro and Revoltella, 1982) , decreased neurons in the superior cervical ganglion (Rich et al., 1984; Ruit et al., 1990) , and decreases in norepinephrine and dopamine levels (Bode et al., 1986; Rich et al., 1984) . decreased sensory and sympathetic neurons (Crowley et al., 1994) , and decreased calcitonin gene-related peptide neurons and immunoreactivity (Crowley et al., 1994) . In these NGF null mutant mice, there is no apparent effect on the cholinergic neurons of the basal forebrain, although effects are seen in heterozygous animals. No effect on cholinergic neurons in the basal forebrain was noted in this study. Neural lesions in NGF knockout mice and animals treated with an anti-NGF antibody extend beyond the brain. For instance, 3-day-old NGF knockout mice have 70% fewer neurons in the fourth and fifth lumbar dorsal root ganglia than homozygous normal (þ/þ) mice (Crowley et al., 1994) . There also was an absence of cells <15 mm in diameter in the cervical and lumbar dorsal root ganglion in knockout mice, but there was no evidence of loss of cells >25 mm. This effect would increase the average neuron size, an effect also noted in the current study on primates exposed in utero. Furthermore, the dorsal root ganglion from NGF knockout mice had only a few cells stained (weakly) with calcitonin gene-related peptide (CGRP) antibody compared with the þ/þ and þ/À mice, in which numerous perikarya were stained with anti-CGRP (Crowley et al., 1994) . Variable effects have been noted in the adrenal medulla (cells that are derived from neural crest cells as are neurons in dorsal root and sympathetic ganglia), ranging from no effect (Gorin and Johnson, 1980 ) to significant degeneration LeviMontalcini, 1979, 1980) . Shrunken and degenerating neurons have been reported in the superior cervical ganglia (SCG) in rodents treated with anti-NGF (Johnson et al., 1989; Schwartz et al., 1982) , although in the opinion of the lead author of the current manuscript, careful review of the literature does not reveal convincing morphologic evidence of active neuronal degeneration (except for decreased neuron size) or necrosis.
Finally, the SCG in both neonatal NGF knockout mice and in mice treated with NGF antibodies are significantly smaller than control mice (Businaro and Revoltella, 1982; Crowley et al., 1994) .
The findings of the current study were often similar to those reported to occur in rodents and extend our knowledge of the role of endogenous NGF during development of the nervous system in nonhuman primates.
As noted above in published studies on anti-NGF states in rodents, presumed prenatal exposure to tanezumab resulted in pronounced effects on the sensory and sympathetic components of the peripheral nervous system, including a decrease of postganglionic sympathetic neurons (those that reside in the sympathetic ganglia), as determined during light microscopic evaluation; a decrease in total MNFs and UNFs in a peripheral nerve (sural nerve), as determined using specific quantitative techniques; and a decrease in the number of dorsal root ganglion neurons, as determined using stereologic investigation. None of the neuron effects, including the decrease of neurons in the sympathetic ganglia, were associated with active neuronal necrosis or degeneration, suggesting the pathogenesis was likely hypoplasia (failure of neurons to develop) and/or apoptosis of the neurons, as has been shown in rodents. Early necrosis cannot be ruled out since necrosis of susceptible neuronal populations may occur following a single exposure to a neurotoxicant, and evidence (cellular debris) of neuronal necrosis (typically) quickly clears within 7 days (or less) following cell death (Switzer et al., 2011) . Given the quick loss of evidence, it is possible that the timing of tissue collection in the current study was partially responsible for the lack of observed neuronal degeneration/ necrosis.
Tanezumab was no longer detectable in infants up to DB30, DB120, and DB127 in the 0.5, 4, and 30 mg/kg groups respectively, but the lack of morphologic abnormalities (e.g., degeneration, demyelination, or remyelination/regeneration) in the MNFs and the decrease of total MNFs and UNFs indicated the effect of tanezumab treatment was likely due to a failure of the neurons/axons to develop (hypoplasia/aplasia) or atrophy, as opposed to ongoing/persistent neuron/axon degeneration. Interestingly, despite these changes in the anatomy of the peripheral nervous system, no detectable functional effects (behavior and cognition) were detected in these animals. Any relationship these changes in ganglia/neurons/nerves in the peripheral nervous system had to the increased unscheduled infant deaths (Table 2) was not apparent.
Further research into the actual cause of these peripheral nervous system effects is warranted, but the existing evidence suggests that exposure of nonhuman primates to anti-NGF antibodies at these levels may result in significant changes in neuronal development consistent with those previously seen in the developing rodent.
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